Cleveland BioLabs Announces Appointment of Biotechnology Industry Veteran, Langdon Miller, MD, as President and Chief Medical Officer
May 05, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - May 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Langdon L. Miller, M.D., as President and Chief Medical Officer, effective...
Cleveland BioLabs to Report First Quarter 2015 Financial Results on May 6
April 30, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 30, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on May 6, 2015, it will report its financial results for the first quarter ended March...
Cleveland BioLabs Enters Into Agreement to Raise Up to $4 Million Through Sales of Equity Stake in Incuron Joint Venture
April 29, 2015 09:54 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 29, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has entered into an agreement to sell its equity stake in Incuron, LLC (Incuron) to Dr....
Cleveland BioLabs and Roswell Park Cancer Institute Announce Award of Department of Defense Breast Cancer Research Program Breakthrough Grant for Entolimod
April 27, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 27, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the award of a three-year, $1.2 million Breast Cancer...
Cleveland BioLabs Announces Acceptance of Entolimod Phase 1 Study Findings for Poster Presentation at ASCO
April 22, 2015 09:12 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 22, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that findings from a Phase 1 clinical study of entolimod (previously known as CBLB502) have been...
Cleveland BioLabs Receives Funding Recommendation From Department of Defense for Additional Development Proposal for Entolimod (CBLB502) as a Medical Radiation Countermeasure
April 14, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 14, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company received notice that a second proposal application to support further development...
Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612
April 02, 2015 08:00 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of a U.S. patent application, to issue as U.S. Patent No. 9,006,183, covering...
Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation
March 16, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Mar 16, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a maximally tolerated dose has been reached and that dosing has been completed in a Phase 1...
Cleveland BioLabs and Incuron Announce Growth of Curaxin CBL0137 Patent Portfolio With U.S. Composition of Matter Patent
March 02, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Mar 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Incuron LLC, a joint venture between the CBLI and Bioprocess Capital Ventures, announce the issuance of a...
Cleveland BioLabs Reports Fourth Quarter and Fiscal 2014 Financial Results and Development Progress
February 24, 2015 07:30 ET
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 24, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and fiscal year ended December...